CD5 chimeric antigen receptor for adoptive T cell therapy
AssigneeBaylor College of Medicine
InventorsMaksim Mamonkin, Malcolm K. Brenner
Life of this patent
Estimating the term…
Abstract
Embodiments of the disclosure include methods and compositions related to immunotherapy that targets CD5. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor (CAR) that targets CD5 are contemplated, and uses thereof. In particular embodiments, the immune cells expressing the CAR do not commit fratricide to any great extent against T cells that express CD5 and which are endogenous to an individual receiving the immune cells.
Claims23
A method of inhibiting proliferation and/or activity of CD5-positive cells in an individual, comprising the step of contacting the cells with a therapeutically effective amount of immune cells that express a chimeric antigen receptor (CAR) that targets CD5, wherein the CAR comprises the amino acid sequence of SEQ ID NO:
- 13 or SEQ ID NO:
- 14.
A method of treating an individual having a leukemia or lymphoma of a T cell lineage that expresses CD5, comprising the step of providing to the individual a therapeutically effective amount of immune cells comprising a single genetic modification, wherein the single genetic modification is expression of a chimeric antigen receptor (CAR) that targets CD5, wherein the immune cells are T cells that lack surface expression of CD5 sufficient to cause fratricide.
A method of treating an individual having a CD5-expressing cancer, comprising the step of providing to the individual a therapeutically effective amount of immune cells that express a chimeric antigen receptor (CAR) that targets CD5, wherein the CAR comprises the amino acid sequence of SEQ ID NO:
- 13 or SEQ ID NO:
- 14.
Dependencies are inferred from the claim text.